Ildong Pharmaceutical "Approval for Amendment of Phase 2/3 Clinical Trial Plan for Oral COVID-19 Treatment"
[Asia Economy Reporter Lee Seon-ae] Ildong Pharmaceutical announced on the 24th that it has received approval from the Ministry of Food and Drug Safety for the modification of the Phase 2/3 clinical trial plan of the oral COVID-19 treatment candidate 'S-217622'.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051414165763158_1778735817.jpg)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- [Breaking] Park Sukeun, Central Labor Relations Commission Chair: "Some Gaps Narrowed Between Samsung Electronics Labor and Management"
- Is This the Peak? As Others Hesitate..."The Answer Is Clear for Surviving the KOSPI 10,000 Era"
- "If That's the Case, Why Not Just Buy Stocks?" ETFs in Name Only, Now 'Semiconductor-Heavy' and a Playground for Short-Term Traders
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
